# Renoprotective Action of Linagliptin Among Diabetic Kidney Disease Patients: A Systematic Review and Meta-Analysis

## TL;DR

This study reviews whether linagliptin helps protect kidneys in type 2 diabetes patients, finding no significant benefit.

## Contribution

A systematic review and meta-analysis evaluating linagliptin's renoprotective effects in diabetic nephropathy patients.

## Key findings

- Linagliptin showed no significant improvement in estimated glomerular filtration rate (eGFR) compared to placebo.
- No substantial renoprotective benefit was observed in patients with type 2 diabetes and kidney disease.
- More long-term studies are needed to confirm linagliptin's effectiveness in slowing kidney disease progression.

## Abstract

Despite pharmacological and lifestyle changes, hyperglycemia management in type 2 diabetes mellitus patients, combined with a risk for cardio-renal problems, continues to present a significant challenge for doctors. Linagliptin has been found to have a renoprotective effect in diabetic nephropathy patients in recent studies. This systematic review and meta-analysis (SRMA) was conducted to synthesize available information so as to better understand if linagliptin has a renoprotective effect in type 2 diabetes mellitus patients with nephropathy. Three databases were searched from January 2013 to December 2022 to identify all published studies reporting “linagliptin’s effect in patients with diabetic nephropathy”. Owing to the heterogeneity of the included studies, the authors have employed a random-effects model to examine the data in this meta-analysis. Standardized mean differences (SMD) for continuous outcomes were used to compute effect sizes. The final analysis included five studies. The change in estimated glomerular filtration rate (eGFR) did not show a statistically significant difference between the group on linagliptin and the other group on placebo, at baseline (mean difference = 1.19, p = 0.28), after three months of intervention in the selected three studies (mean difference = 0.51, p = 0.85), and after six months of intervention in the selected two studies (mean difference = 0.72, p = 0.70). The study found that linagliptin did not have a significant renoprotective effect in patients with type 2 diabetes, indicating no substantial benefit in slowing kidney disease progression. For diabetes patients with chronic renal disease, linagliptin may be a helpful renoprotective treatment choice, but in the future, more robust and longer-duration research is warranted to establish the inference.